生物医药领域“准独角兽企业”——英百瑞浙江省企业研究院正式揭牌，医学研究中心入驻启用，加速领跑通用现货型NK细胞治疗赛道

Core Viewpoint - The establishment of the Yingbairui Medical Research Center marks a significant milestone for the company, enhancing its position in the global NK cell therapy market and advancing its research and development capabilities in immunotherapy [1][3][7]. Group 1: Company Developments - Yingbairui (Hangzhou) Biopharmaceutical Co., Ltd. held a grand unveiling ceremony for the Zhejiang Provincial Enterprise Research Institute and the Yingbairui Medical Research Center, attended by government officials, industry partners, and the company's leadership [1][3]. - The company aims to strengthen its core technology research and development, focusing on clinical applications and the transformation of immunotherapy solutions [3][9]. - Yingbairui has established a comprehensive product line that includes four core products targeting various diseases, with multiple products already in clinical phase II trials, showcasing significant clinical application value [11]. Group 2: Industry Impact - The biopharmaceutical industry is recognized as a strategic emerging industry, with Yingbairui's advancements expected to inject strong momentum into the growth of the biopharmaceutical cluster in the region [5]. - The company's "off-the-shelf" technology significantly reduces treatment costs and time, making advanced cell therapies more accessible to a broader population [5][9]. - The collaboration with Beijing Deep Intelligence aims to integrate AI technology into the ACC-NK cell therapy platform, enhancing the development cycle and pushing the immunotherapy industry towards precision, intelligence, and scalability [12][14]. Group 3: Future Strategies - Yingbairui's future strategy includes enhancing clinical applications, drug development under GCP guidelines, and focusing on anti-aging and longevity drug research [9][16]. - The company is committed to continuous innovation in NK cell therapy, addressing the scientific effectiveness, clinical practicality, and social accessibility of its treatments [16].